Trial Profile
PGT102 phase I study of XYOTAX™ (CT-2103) [paclitaxel poliglumex; Cell Therapeutics] administered weekly for patients with advanced solid tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 18 Nov 2005
Price :
$35
*
At a glance
- Drugs Paclitaxel poliglumex (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 18 Nov 2005 New trial record.